gemcitabine sustained release (ST-02)
/ Sustained Therap
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
July 17, 2024
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
(clinicaltrials.gov)
- P2/3 | N=70 | Recruiting | Sponsor: University of British Columbia | Initiation date: Mar 2024 ➔ Jun 2024
Trial initiation date • Genito-urinary Cancer • Kidney Cancer • Oncology • Solid Tumor • Urothelial Cancer
June 24, 2024
Sustained Therapeutics Announces First Patient for Cancer Trial
(PRNewswire)
- "The first patient has entered the Phase II/III trial of ST-02, Sustained Therapeutic's innovative cancer medication targeting Upper Tract Urethral Carcinoma (UTUC)....The first patient in the clinical trial has been enrolled at the Vancouver Prostate Centre, and it is anticipated that 5 other sites will take part in the study. The company plans on enrolling approximately 75 patients in the combined Phase II/III trial and believes that ST-02 may be designated an orphan drug."
Trial status • Urethral Cancer
April 01, 2024
Multicenter Clinical Trial of ST-02 for Ablation of Upper Tract Urothelial Carcinoma
(clinicaltrials.gov)
- P2/3 | N=70 | Recruiting | Sponsor: University of British Columbia | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Apr 2026 | Trial primary completion date: Dec 2025 ➔ Apr 2026
Enrollment open • Trial completion date • Trial primary completion date • Genito-urinary Cancer • Kidney Cancer • Oncology • Solid Tumor • Urothelial Cancer
November 16, 2023
Sustained Therapeutics announces clinical trial of second product
(Canada Newswire)
- "Sustained Therapeutics...announced today regulatory clearance for a pivotal Phase II/III human trial of its second product...for the treatment of a rare form of cancer. Upper Tract Urethral Carcinoma ('UTUC') is an orphan disease, a malignancy of the cells lining the renal pelvis....The Company's product ('ST-02') is delivered directly to the site of the carcinoma in the renal pelvis through a ureteric catheter, rather than via infusion or systemic delivery, and then releases slowly."
New P2/3 trial • Genito-urinary Cancer • Oncology • Solid Tumor • Urethral Cancer
1 to 4
Of
4
Go to page
1